Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations

Chinese Medical Journal

Volumn 122, Issue 9, 2009, Pages 1081-1086

  Li, Jue ^a   Li, Lin ^a   Li, Han Ping ^a   Zhuang, Dao Min ^a   Liu, Si Yang ^a   Liu, Yong Jian ^a   Bao, Zuo Yi ^a   Wang, Zheng ^a   Li, Jing Yun ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Drug resistance; Human immunodeficiency virus type 1; Replication capacity

Indexed keywords

LAMIVUDINE; NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; COCULTURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS GENOME; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

CELL LINE; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; LAMIVUDINE; MUTATION; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

EID: 68149099922     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.09.013     Document Type: Article

References (30)

1. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283: 229-234.
2. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu. Rev Microbiol 1997; 51: 151-178.
3. Albert J, Wahlberg J, Lundeberg J, Cox S, Sandström E, Wahren B, et al. Persistence of azidothymidine-resistant human immunode-ficiency virus type 1 RNA genotypes in posttreatment sera. J Virol 1992; 66: 5627-5630.
4. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472-480.
5. Lu JF, Li J, Li HP, Liu SY, Zhuang DM, Liu YJ, et al. Experimental and clinical research of HIV-1 resistance in three AIDS patients who had experienced multiple regimens. Chin Med J 2009; 122: 752-754.
6. Wang FX, Zhou H, Ling H, Zhou HZ, Liu WH. Subtype and sequence analysis of HIV-1 strains in Heilongjiang Province. Chin Med J 2007; 120: 2006-2010.
7. Li J, Lu JF, Dong HH, Bao ZY, Liu SY, Li HP, et al. Phenotypic resistance of resistant strains of HIV type-1 subtype B in China. Chin Med J 2006; 119: 1972-1977.
8. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. Evolution of lamivudine resistance in human immuno-deficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 2000; 74: 6262-6268.
9. Quan Y, Gu Z, Li X, Li Z, Morrow CD, Wainberg MA. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2pm-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol 1996; 70: 5642-5645.
10. Ho DD, Neumann AU, Perelson AS, ChenW, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
11. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122.
12. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90: 5653-5656.
13. Kavlick MF, Shirasaka T, Kojima E, Pluda JM, Hui F Jr, Yarchoan R, et al. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′- dideoxy-3′-thiacytidine. Antivir Res 1995; 28: 133-146.
14. Kosalaraksa P, Kavlick MF, Maroun V, Le R, Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J Virol 1999; 73: 5356-5363.
15. Qiu YL, Ksebati MB, Ptak RG, Fan BY, Breitenbach JM, Lin JS, et al. (Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)- methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity. J Med Chem 1998; 41: 10-23.
16. Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 2231-2234.
17. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001; 14: 23-28.
18. Klein SA, Karsten S, Rüster B, Klebba C, Pape M, Ottmann OG, et al. Comparison of TaqMan real-time PCR and p24 ELISA for quantification of in vitro HIV-1 replication. J Virol Methods 2003; 107: 169-175.
19. Lu J, Kuritzkes DR. A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants. J Acquir Immune Defic Syndr 2001; 27: 7-13.
20. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002; 16: 1009-1017.
21. Devereux HL, Emery VC, Johnson MA, Loveday C. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 2001; 65: 218-224.
22. Zaccarelli M, Perno CF, Forbici F, Cingolani A, Liuzzi G, Bertoli A, et al. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. Antivir Ther 2003; 8: 51-56.
23. Collins JA, Thompson MG, Paintsil E, Ricketts M, Gedzior J, Alexander L. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 2004; 78: 603-611.
24. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Brown AJ, Savara AV, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000; 181: 904-911.
25. Borman AM, Paulous S, Clavel F. Resistance of human immunodeciency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 1996; 77: 419-426.
26. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor crossresistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188: 992-1000.
27. de la Torre JC, Holland JJ. RNA virus quasispecies populations can suppress vastly superior mutant progeny. J Virol 1990; 64: 6278-6281.
28. Miralles R, Gerrish PJ, Moya A, Elena SF. Clonal interference and the evolution of RNA viruses. Science 1999; 285: 1745-1747.
29. Ayala FJ. Competition between species: frequency dependence. Science 1971; 171: 820-824.
30. Zhang FJ, Maria A, Haberer J, Zhao Y. Overview of HIV drug resistance and its implications for China. Chin Med J 2006; 119: 1999-2004.